PT  - JOURNAL ARTICLE
AU  - Mortari, Eva Piano
AU  - Russo, Cristina
AU  - Vinci, Maria Rosaria
AU  - Terreri, Sara
AU  - Salinas, Ane Fernandez
AU  - Piccioni, Livia
AU  - Alteri, Claudia
AU  - Colagrossi, Luna
AU  - Coltella, Luana
AU  - Ranno, Stefania
AU  - Linardos, Giulia
AU  - Agosta, Marilena
AU  - Albano, Christian
AU  - Agrati, Chiara
AU  - Castilletti, Concetta
AU  - Meschi, Silvia
AU  - Romania, Paolo
AU  - Roscilli, Giuseppe
AU  - Pavoni, Emiliano
AU  - Camisa, Vincenzo
AU  - Santoro, Annapaola
AU  - Brugaletta, Rita
AU  - Magnavita, Nicola
AU  - Ruggiero, Alessandra
AU  - Cotugno, Nicola
AU  - Amodio, Donato
AU  - Atti, Marta Luisa Ciofi Degli
AU  - Giorgio, Daniela
AU  - Russo, Nicoletta
AU  - Salvatori, Guglielmo
AU  - Corsetti, Tiziana
AU  - Locatelli, Franco
AU  - Perno, Carlo Federico
AU  - Zaffina, Salvatore
AU  - Carsetti, Rita
TI  - Highly-specific memory B cells generation after the 2<sup>nd</sup> dose of BNT162b2 vaccine compensate for the decline of serum antibodies and absence of mucosal IgA
AID  - 10.1101/2021.06.08.21258284
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.06.08.21258284
4099  - http://medrxiv.org/content/early/2021/06/09/2021.06.08.21258284.short
4100  - http://medrxiv.org/content/early/2021/06/09/2021.06.08.21258284.full
AB  - Specific memory B cells and antibodies are reliable read-out of vaccine efficacy. We analyzed these biomarkers after one and two doses of BNT162b2 vaccine. The second dose significantly increases the level of highly-specific memory B cells and antibodies. Two months after the second dose, specific antibody levels decline, but highly specific memory B cells continue to increase thus predicting a sustained protection from COVID-19. Graphical AbstractCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis work was founded by: Italian Ministry of Health RF2013-02358960 grant Italian Ministry of Health COVID-2020-12371817 grant Ricerca Corrente 2021 5 per mille Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was obtained from the Ethics Committee at OPBG, Bambino Gesu Children Hospital. According to the guidelines on Italian observational studies as established by the Italian legislation about the obligatory occupational surveillance and privacy management; Health Care Wokers (HCWs) confidentiality was safeguarded, and informed consent was obtained from all the participants. The study was performed in accordance with the Good Clinical Practice guidelines, the International Conference on Harmonization guidelines, and the most recent version of the Declaration of Helsinki.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available in the main text or the supplementary materials.